Nourianz Approved to Treat 'Off' Episodes in Parkinson Disease
WEDNESDAY, Aug. 28, 2019 -- Nourianz (istradefylline) tablets have been approved as an add-on treatment to levodopa/carbidopa for adults with Parkinson disease experiencing "off" episodes, the U.S. Food and Drug Administration announced yesterday.
The drug is available in 20-mg or 40-mg doses, but the maximum recommended dosage in patients taking CYP3A4 inhibitors and those with moderate hepatic impairment is 20 mg once daily. The safety information for Nourianz states that use of the drug should be avoided in these patient populations.
Data from four 12-week placebo-controlled clinical studies demonstrated the effectiveness of Nourianz, a selective adenosine A2A receptor antagonist, in treating "off" episodes in 1,143 PD patients who were receiving treatment with levodopa/carbidopa. Compared with patients who received placebo, patients who received Nourianz experienced a statistically significant decrease in daily "off" time from baseline.
The most commonly reported adverse reactions with Nourianz included dyskinesia, dizziness, constipation, nausea, hallucination, and insomnia. The FDA noted that physicians should monitor patients for development or progression of dyskinesia while taking Nourianz. A reduction in dosage or stoppage of Nourianz should be considered in the case of hallucinations, psychotic behavior, or impulsive/compulsive behavior. Nourianz should not be used during pregnancy, and women with childbearing potential should use contraception during treatment.
Approval was granted to Kyowa Kirin.
© 2020 HealthDay. All rights reserved.
Posted: August 2019
Read this next
MONDAY, Oct. 26, 2020 -- If you're a senior who can't smell onions, smoke, chocolate or natural gas, it's time to see your doctor. Seniors who lose their sense of smell -- which...
TUESDAY, Oct. 20, 2020 -- As the air people breathe gets dirtier, their odds for serious neurological disorders such as Parkinson's disease, Alzheimer's and other dementias rises,...
MONDAY, Oct. 5, 2020 -- Caffeine may reduce the risk of Parkinson's disease in people who have a gene mutation associated with the movement disorder, researchers report. "These...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.